Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AORT Artivion	$28.92 -0.7%	$25.96	$21.97 ▼ $32.33	$1.24B	1.62	332,121 shs	137,254 shs
IRTC iRhythm Technologies	$146.09 +0.6%	$121.58	$55.92 ▼ $147.18	$4.66B	1.34	482,179 shs	117,954 shs
NARI Inari Medical	$79.97	$79.97	$39.76 ▼ $79.99	$4.68B	1.02	1.35 million shs	N/A
TMDX TransMedics Group	$137.14 +1.1%	$100.13	$55.00 ▼ $177.37	$4.64B	2.1	1.36 million shs	426,034 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AORT Artivion	+1.73%	-2.23%	+6.10%	+20.25%	+24.25%
IRTC iRhythm Technologies	+0.97%	+2.10%	+7.50%	+42.73%	+60.46%
NARI Inari Medical	0.00%	0.00%	0.00%	0.00%	+58.83%
TMDX TransMedics Group	+4.45%	+6.19%	+45.20%	+100.99%	+0.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AORT Artivion	1.5772 of 5 stars	1.6	1.0	0.0	0.0	3.3	2.5	1.9
IRTC iRhythm Technologies	1.1204 of 5 stars	2.5	3.0	0.0	0.0	1.5	0.0	0.6
NARI Inari Medical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TMDX TransMedics Group	1.7331 of 5 stars	1.4	3.0	0.0	0.0	2.5	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AORT Artivion	3.17	Buy	$31.40	8.59% Upside
IRTC iRhythm Technologies	2.91	Moderate Buy	$133.73	-8.46% Downside
NARI Inari Medical	2.14	Hold	$69.22	-13.44% Downside
TMDX TransMedics Group	2.80	Moderate Buy	$125.11	-8.77% Downside

Current Analyst Ratings Breakdown

Latest AORT, NARI, IRTC, and TMDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	TMDX TransMedics Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$125.00 ➝ $145.00
6/3/2025	TMDX TransMedics Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/22/2025	IRTC iRhythm Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$130.00 ➝ $167.00
5/9/2025	TMDX TransMedics Group	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$125.00 ➝ $130.00
5/9/2025	TMDX TransMedics Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00 ➝ $125.00
5/6/2025	AORT Artivion	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/6/2025	AORT Artivion	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$33.00 ➝ $33.00
5/6/2025	AORT Artivion	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
5/2/2025	IRTC iRhythm Technologies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$152.00 ➝ $139.00
5/2/2025	IRTC iRhythm Technologies	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$133.00 ➝ $150.00
5/2/2025	IRTC iRhythm Technologies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$104.00 ➝ $130.00

(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AORT Artivion	$390.08M	3.17	$0.79 per share	36.78	$6.87 per share	4.21
IRTC iRhythm Technologies	$618.59M	7.54	N/A	N/A	$6.85 per share	21.33
NARI Inari Medical	$493.63M	9.48	$0.09 per share	906.95	$8.07 per share	9.91
TMDX TransMedics Group	$488.23M	9.50	$0.26 per share	530.08	$4.20 per share	32.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AORT Artivion	-$30.69M	-$0.50	N/A	57.83	N/A	-0.22%	5.15%	1.91%	8/14/2025 (Estimated)
IRTC iRhythm Technologies	-$123.41M	-$3.14	N/A	N/A	N/A	-19.14%	-118.83%	-11.34%	7/30/2025 (Estimated)
NARI Inari Medical	-$1.64M	-$1.35	N/A	727.00	N/A	-13.68%	-10.09%	-6.60%	N/A
TMDX TransMedics Group	-$25.03M	$1.36	145.83	95.90	N/A	8.14%	18.74%	4.39%	7/30/2025 (Estimated)

Latest AORT, NARI, IRTC, and TMDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	TMDX TransMedics Group	$0.29	$0.70	+$0.41	$0.70	$123.39 million	$143.54 million
5/5/2025	Q1 2025	AORT Artivion	$0.12	$0.06	-$0.06	-$0.01	$94.81 million	$98.98 million
5/1/2025	Q1 2025	IRTC iRhythm Technologies	-$0.89	-$0.95	-$0.06	-$0.97	$153.39 million	$158.68 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AORT Artivion	N/A	N/A	N/A	N/A	N/A
IRTC iRhythm Technologies	N/A	N/A	N/A	N/A	N/A
NARI Inari Medical	N/A	N/A	N/A	N/A	N/A
TMDX TransMedics Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AORT Artivion	0.71	1.88	1.33
IRTC iRhythm Technologies	9.00	6.27	6.12
NARI Inari Medical	N/A	1.77	1.40
TMDX TransMedics Group	2.42	8.20	7.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AORT Artivion	86.37%
IRTC iRhythm Technologies	N/A
NARI Inari Medical	90.98%
TMDX TransMedics Group	99.67%

Insider Ownership

Company	Insider Ownership
AORT Artivion	7.60%
IRTC iRhythm Technologies	1.10%
NARI Inari Medical	10.60%
TMDX TransMedics Group	7.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AORT Artivion	1,300	42.70 million	38.52 million	Optionable
IRTC iRhythm Technologies	1,790	31.93 million	31.09 million	Optionable
NARI Inari Medical	800	58.54 million	52.34 million	Optionable
TMDX TransMedics Group	210	33.82 million	31.21 million	Optionable

AORT, NARI, IRTC, and TMDX Headlines

Recent News About These Companies

TransMedics Group (NASDAQ:TMDX) Earns "Overweight" Rating from Piper Sandler

June 6 at 1:33 AM | americanbankingnews.com

3 High-Growth Stocks Traders Love and Investors Should Watch (TMDX)

June 5 at 10:02 AM | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Investors to Connect

June 5 at 10:00 AM | accessnewswire.com

Sugar Maple Asset Management LLC Makes New $740,000 Investment in TransMedics Group, Inc. (NASDAQ:TMDX)

June 5 at 6:47 AM | marketbeat.com

TransMedics Group's (TMDX) Hold Rating Reiterated at Needham & Company LLC

June 5 at 1:19 AM | americanbankingnews.com

Piper Sandler Boosts TransMedics (TMDX) PT to $145, Keeps Overweight Rating

June 4 at 9:20 PM | msn.com

TransMedics Group's (TMDX) "Overweight" Rating Reiterated at Piper Sandler

June 4 at 1:58 PM | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities Investigation

June 3 at 10:00 AM | accessnewswire.com

TransMedics Group's (TMDX) "Hold" Rating Reaffirmed at Needham & Company LLC

June 3 at 8:11 AM | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX) and Merck & Company (MRK)

June 3 at 6:36 AM | theglobeandmail.com

Wellington Management Group LLP Cuts Position in TransMedics Group, Inc. (NASDAQ:TMDX)

June 3 at 4:27 AM | marketbeat.com

TransMedics (TMDX) Just Flashed Golden Cross Signal: Do You Buy?

June 2, 2025 | zacks.com

Universal Beteiligungs und Servicegesellschaft mbH Buys New Shares in TransMedics Group, Inc. (NASDAQ:TMDX)

June 2, 2025 | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Investors to Inquire about Securities Investigation

June 1, 2025 | accessnewswire.com

Nuveen Asset Management LLC Reduces Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

June 1, 2025 | marketbeat.com

Edward M. Basile Sells 5,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

May 31, 2025 | marketbeat.com

TransMedics Group, Inc. (NASDAQ:TMDX) Director Sells $632,250.00 in Stock

May 30, 2025 | insidertrades.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Investors to Reach Out

May 29, 2025 | accessnewswire.com

Spotlight on TransMedics Group Inc Top Companies in the Nasdaq

May 29, 2025 | kalkinemedia.com

Kuehn Law Encourages Investors of TransMedics Group, Inc. to Contact Law Firm

May 27, 2025 | prnewswire.com

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 27, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
These 3 Stocks Are Buying Back Billions in Shares
By Leo Miller | June 3, 2025
View These 3 Stocks Are Buying Back Billions in Shares
Survey: America’s Most Inspirational Women Business Leaders [2025]
By MarketBeat Staff | May 7, 2025
View Survey: America’s Most Inspirational Women Business Leaders [2025]

AORT, NARI, IRTC, and TMDX Company Descriptions

Artivion NYSE:AORT

$28.92 -0.21 (-0.70%)

As of 01:31 PM Eastern

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

iRhythm Technologies NASDAQ:IRTC

$146.09 +0.86 (+0.59%)

As of 01:31 PM Eastern

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Inari Medical NASDAQ:NARI

$79.97 0.00 (0.00%)

As of 02/19/2025

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

TransMedics Group NASDAQ:TMDX

$137.14 +1.55 (+1.14%)

As of 01:31 PM Eastern

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time